Why does GLP‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP‐1 agonist alone in obese adults without type 2 diabetes? DOI
Yuchen Jiang, Huijuan Zhu, Fengying Gong

et al.

Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 26, 2024

Abstract Obesity is a chronic condition demanding effective treatment strategies, among which pharmacotherapy plays critical role. As glucagon‐like peptide‐1 (GLP‐1) agonist approved by the Food and Drug Administration (FDA) for long‐term weight management in adults with obesity, liraglutide semaglutide have great loss effect through reducing food intake delaying gastric emptying. The emergence of unimolecular polypharmacology, utilizes single molecules to simultaneously target multiple receptors or pathways, marked revolutionary improvement GLP‐1‐based obesity pharmacotherapy. dual tirzepatide activates both GLP‐1 glucose‐dependent insulinotropic polypeptide (GIP) has shown enhanced potency compared conventional mono agonist. Furthermore, emerging data suggests that GLP‐1/glucagon (GCG) agonist, as well GLP‐1/GIP/GCG triple may offer superior efficacy over This review summarizes comprehensive mechanisms underlying pronounced advantages GLP‐1/GIP GLP‐1/GCG reduction obese without type 2 diabetes. A deeper understanding these multitargeting agonists will provide insights their clinical application guide development new drugs treatment.

Language: Английский

Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes DOI

Zhimin Xu,

Song Wen, Meiyuan Dong

et al.

Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 26, 2024

Abstract Obesity and type 2 diabetes are significant public health challenges that greatly impact global well‐being. The development of effective therapeutic strategies has become more concentrated on the central nervous system metabolic regulation. primary pharmaceutical interventions for treatment obesity uncontrolled hyperglycemia now generally considered to be incretin‐based anti‐diabetic treatments, particularly glucagon‐like peptide‐1 glucose‐dependent insulinotropic polypeptide receptor agonists. This is a result their substantial influence consequent effects energy balance glucose It increasingly crucial understand neural pathways these pharmaceuticals. purpose this review compile present most recent regarding peptide‐1, glucagon receptors, with particular emphasis

Language: Английский

Citations

2
Why does GLP‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP‐1 agonist alone in obese adults without type 2 diabetes? DOI
Yuchen Jiang, Huijuan Zhu, Fengying Gong

et al.

Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 26, 2024

Abstract Obesity is a chronic condition demanding effective treatment strategies, among which pharmacotherapy plays critical role. As glucagon‐like peptide‐1 (GLP‐1) agonist approved by the Food and Drug Administration (FDA) for long‐term weight management in adults with obesity, liraglutide semaglutide have great loss effect through reducing food intake delaying gastric emptying. The emergence of unimolecular polypharmacology, utilizes single molecules to simultaneously target multiple receptors or pathways, marked revolutionary improvement GLP‐1‐based obesity pharmacotherapy. dual tirzepatide activates both GLP‐1 glucose‐dependent insulinotropic polypeptide (GIP) has shown enhanced potency compared conventional mono agonist. Furthermore, emerging data suggests that GLP‐1/glucagon (GCG) agonist, as well GLP‐1/GIP/GCG triple may offer superior efficacy over This review summarizes comprehensive mechanisms underlying pronounced advantages GLP‐1/GIP GLP‐1/GCG reduction obese without type 2 diabetes. A deeper understanding these multitargeting agonists will provide insights their clinical application guide development new drugs treatment.

Language: Английский

Citations

1